

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Pharmaron Beijing Co., Ltd.*

康龍化成(北京)新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

**ANNOUNCEMENT ON
THE FINAL NUMBER OF ADDITIONAL CONVERSION SHARES
TO BE ISSUED UNDER
THE CONVERTIBLE BONDS-RELATED SPECIFIC MANDATE**

References are made to the announcement of Pharmaron Beijing Co., Ltd.* (the “**Company**”) dated April 20, 2022 (the “**Announcement**”) and the circular of the Company dated May 6, 2022 (the “**Circular**”) in relation to, among other things, the proposed grant of the Convertible Bonds-Related Specific Mandate to issue the Additional Conversion Shares. Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Circular.

As disclosed in the Announcement and the Circular, the Series 1 Bonds Adjusted Conversion Price, the Series 2 Bonds Adjusted Conversion Price and the number of Additional Conversion Shares to be issued may be subject to necessary adjustments by the Board pursuant to (among other things) the Terms and Conditions. In particular, the exchange rate to be used for calculation of the Conversion Price shall be the average of the medium rate of RMB to HK\$ announced by the People's Bank of China for five working days prior to May 31, 2022, the date on which the 2021 Profit Distribution Plan is to be considered by the Shareholders at the AGM and Class Meetings (the “**Exchange Rate**”).

Based on the Exchange Rate of HK\$1.00 to RMB0.851826, the respective final Series 1 Bonds Adjusted Conversion Price and the Series 2 Bonds Adjusted Conversion Price remain the same as those disclosed in the Circular. The Conversion Price of the Series 1 Bonds and Series 2 Bonds will be adjusted from HK\$250.75 to HK\$166.42 and from HK\$229.50 to HK\$152.32, respectively. Assuming full conversion of the outstanding (i) Series 1 Bonds at the Series 1 Bonds Adjusted Conversion Price and (ii) Series 2 Bonds at the Series 2 Bonds Adjusted Conversion Price, the H Shares that may be convertible and issuable under the outstanding Series 1 Bonds will increase from 9,282,711 H Shares to 13,986,540 H Shares and the H Shares that may be convertible and issuable under the outstanding Series 2 Bonds will increase from 10,137,685 H Shares to 15,274,414 H Shares. Therefore, the final number of Additional Conversion Shares under the Conversion Bond-Related Specific Mandate to be sought at the AGM will be 9,840,558 H Shares.

By order of the Board
Pharmaron Beijing Co., Ltd.*
Dr. Lou Boliang
Chairman

Beijing, the PRC
May 30, 2022

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lo Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Chen Pingjin, Mr. Hu Baifeng, Mr. Li Jiaqing and Mr. Zhou Hongbin as non-executive Directors; Mr. Dai Lixin, Ms. Chen Guoqin, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.

* *For identification purposes only*